The lancet oncology
-
The lancet oncology · Feb 2017
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose. ⋯ None.
-
The lancet oncology · Feb 2017
Randomized Controlled Trial Multicenter Study Comparative StudyPadeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. ⋯ Steba Biotech.
-
The lancet oncology · Feb 2017
Randomized Controlled Trial Multicenter StudyMABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer. ⋯ XBiotech.
-
The lancet oncology · Feb 2017
Randomized Controlled Trial Multicenter Study Comparative StudyTwo-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.
The evidence justifying the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR) is limited. We did a prospective randomised trial to compare the safety of IBBR with an ADM immediately after mastectomy with that of two-stage IBBR. ⋯ Pink Ribbon, Nuts-Ohra, and LifeCell.
-
The lancet oncology · Feb 2017
Multicenter StudyVenetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combination with rituximab. ⋯ AbbVie Inc and Genentech Inc.